Try Calculator
← Back to Compound Library GLP-1 AGONISTS

Tirzepatide

Tirzepatide is a dual receptor agonist that changed what was thought possible with weight loss pharmacotherapy. It activates both GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors simultaneously, and this combination produces significantly better results than GLP-1 drugs alone. In the SURMOUNT-1 trial, tirzepatide produced an average weight loss of 22.5% at the highest dose over 72 weeks, with more than a third of participants losing 25% or more of their body weight. To put that in perspective, a person weighing 250 pounds could lose 50 to 60 pounds. These numbers were previously only achievable through bariatric surgery. In the head-to-head SURMOUNT-5 trial published in the New England Journal of Medicine in 2025, tirzepatide produced 20.2% weight loss compared to 13.7% for semaglutide, demonstrating clear superiority. Tirzepatide is FDA approved under two brand names: Mounjaro for type 2 diabetes (approved May 2022) and Zepbound for obesity (approved November 2023). It is manufactured by Eli Lilly and Company and administered as a once-weekly subcutaneous injection. Research-grade tirzepatide is also available through peptide suppliers in lyophilized powder form. The half-life of tirzepatide is approximately five days, which supports stable blood levels with once-weekly dosing. It is a 39-amino-acid peptide based on the GIP sequence, modified with a C20 fatty diacid moiety that binds albumin to extend its duration of action.

How It Works

GLP-1 Receptor Activation

The GLP-1 receptor is the same target that semaglutide and liraglutide activate. When stimulated, it reduces appetite by acting on hypothalamic hunger centers, slows gastric emptying (so you feel full faster and stay full longer), improves insulin sensitivity and glucose-dependent insulin secretion, and reduces glucagon secretion. This pathway is well established and has been the foundation of incretin-based obesity and diabetes drugs for years.

GIP Receptor Activation

This is what makes tirzepatide fundamentally different. GIP (glucose-dependent insulinotropic polypeptide) is another gut hormone involved in metabolism, secreted from K-cells of the upper small intestine within minutes of food ingestion. For a long time, researchers thought blocking GIP would help with weight loss. It turned out they had it backward: activating GIP alongside GLP-1 produces better results than GLP-1 alone. Tirzepatide is approximately five times more potent at the GIP receptor than the body’s natural GIP hormone. This enhanced GIP activity appears to improve how the body processes fat and may contribute to better tolerability compared to pure GLP-1 drugs. GIP receptor activation also stimulates glucose-dependent insulin secretion, providing complementary metabolic benefits.

The Combined Effect

When both receptors are activated together, the result is stronger appetite suppression than either pathway alone, more efficient blood sugar handling, and emerging evidence that the dual mechanism helps preserve more lean mass during weight loss compared to GLP-1-only drugs. The combined signaling also appears to produce improvements across multiple metabolic parameters, including lipids, blood pressure, and waist circumference, that exceed what GLP-1 monotherapy achieves.

Pharmacokinetics

Tirzepatide’s half-life of approximately five days supports once-weekly dosing with stable blood levels. The C20 fatty diacid modification allows it to bind circulating albumin, which slows renal clearance and extends its duration of action. Peak plasma concentrations occur approximately 8 to 72 hours after subcutaneous injection.

Benefits

Superior Weight Loss

The SURMOUNT-1 trial showed dose-dependent weight loss over 72 weeks: 15.0% at 5 mg, 19.5% at 10 mg, and 22.5% at 15 mg, compared to 3.1% with placebo. At the 15 mg dose, 36% of participants lost 25% or more of their body weight. Weight was still declining at week 72, suggesting that even greater losses may be achievable with longer treatment.

Better Than Semaglutide Head to Head

The SURMOUNT-5 trial directly compared tirzepatide to semaglutide in adults with obesity but without diabetes. Published in the New England Journal of Medicine in May 2025, the results showed tirzepatide at maximum tolerated dose produced 20.2% average weight loss versus 13.7% for semaglutide at maximum tolerated dose over 72 weeks. Tirzepatide was also statistically superior for waist circumference reduction. Notably, gastrointestinal adverse events causing treatment discontinuation were lower with tirzepatide (2.7%) than semaglutide (5.6%).

Powerful Blood Sugar Control

In the SURPASS trials for type 2 diabetes, tirzepatide reduced hemoglobin A1C by up to 2.3%. Some participants achieved normal blood sugar levels without additional diabetes medication. Weight loss in these trials ranged from 15 to 25 pounds depending on dose. The SURPASS-2 trial showed tirzepatide was superior to semaglutide for both A1C reduction and weight loss in people with type 2 diabetes.

Cardiovascular Risk Reduction

A post-hoc analysis of SURMOUNT-5 presented at the European Society of Cardiology (ESC) Congress 2025 demonstrated that tirzepatide achieved a significantly greater reduction in estimated 10-year cardiovascular disease risk compared to semaglutide (2.4% versus 1.4%, p<0.001). Projections suggest tirzepatide could prevent over 3.1 million cardiovascular events across the United States and five European countries over 10 years.

Sleep Apnea Improvement

The SURMOUNT-OSA trial showed that tirzepatide reduced obstructive sleep apnea severity by up to 62.8% as measured by the apnea-hypopnea index at 52 weeks. The improvement in sleep apnea was accompanied by improvements in blood pressure and other cardiometabolic markers.

Testosterone Restoration in Men

Data presented at ENDO 2025 showed that tirzepatide increased total testosterone in men with obesity. This makes physiological sense because excess body fat contains aromatase, the enzyme that converts testosterone to estrogen. Losing fat reduces this conversion, restoring testosterone levels. Men saw improvements in sexual function and quality of life alongside weight loss.

Quality of Life Improvements

The SURMOUNT-2 and SURMOUNT-3 trials included quality-of-life assessments. Tirzepatide was associated with significantly greater improvements in physical and psychosocial aspects of health-related quality of life compared to placebo. Improvements were numerically larger in patients who achieved greater weight reduction thresholds and in those with physical function limitations at baseline.

What the Science Shows

Tirzepatide has one of the most extensive clinical trial datasets of any obesity medication, spanning the SURMOUNT (obesity) and SURPASS (diabetes) programs.

SURMOUNT-1 Trial (2022) Published in the New England Journal of Medicine. A total of 2,539 adults with obesity (without diabetes) were randomized to tirzepatide at 5 mg, 10 mg, or 15 mg or placebo for 72 weeks.

Dose Weight Loss ≥25% Loss Placebo 5 mg weekly 15.0% 15% 3.1% 10 mg weekly 19.5% 27% — 15 mg weekly 22.5% 36% —

SURMOUNT-5 Trial (2025) Published in the New England Journal of Medicine. The first head-to-head comparison of tirzepatide versus semaglutide. A total of 751 adults with obesity (without diabetes) were randomized to maximum tolerated dose of tirzepatide (10 mg or 15 mg) or semaglutide (1.7 mg or 2.4 mg) for 72 weeks. Tirzepatide produced 20.2% weight loss versus 13.7% for semaglutide (p<0.001). Tirzepatide was also superior for waist circumference reduction and achieved higher proportions of patients reaching 10%, 15%, 20%, and 25% weight loss thresholds. Weight loss was approximately 6% lower in men than women in both groups, a finding that may explain slightly lower overall results compared to SURMOUNT-1.

SURPASS-2 Trial (2021) Published in the New England Journal of Medicine. Compared tirzepatide to semaglutide 1 mg in people with type 2 diabetes. Tirzepatide produced greater reductions in hemoglobin A1C and greater weight loss at all dose levels (5 mg, 10 mg, and 15 mg) compared to semaglutide 1 mg. This established tirzepatide’s superiority for glycemic control in the diabetes population.

SURMOUNT-OSA Trial (2024) Published in the New England Journal of Medicine. Studied tirzepatide in people with obesity and moderate-to-severe obstructive sleep apnea. At 52 weeks, tirzepatide reduced sleep apnea severity by up to 62.8% as measured by the apnea-hypopnea index, alongside significant weight loss and blood pressure improvements.

SURMOUNT-4 Trial – Weight Regain Analysis (2025) A post-hoc analysis published in JAMA Internal Medicine examined what happens when tirzepatide is discontinued. Among participants who achieved 10% or greater weight reduction during 36 weeks of treatment, withdrawing tirzepatide led to 25% or greater weight regain in most participants within one year. This was accompanied by reversal of cardiometabolic improvements, underscoring that long-term or indefinite treatment may be necessary to maintain results.

SURMOUNT-3 Trial

Evaluated tirzepatide in adults with obesity who had already achieved at least 5% weight reduction through a 12-week intensive lifestyle intervention. Tirzepatide produced significantly greater additional weight loss compared to placebo and was associated with improvements in health-related quality of life across multiple domains.

Cardiovascular Risk Analysis (ESC 2025) A post-hoc analysis of SURMOUNT-5 presented at the European Society of Cardiology Congress demonstrated significantly greater 10-year cardiovascular risk reduction with tirzepatide versus semaglutide (2.4% versus 1.4%, p<0.001). This separation was visible as early as 12 weeks. Projections estimated tirzepatide could prevent over 3.1 million CVD events in the US and major European countries over 10 years, compared to 1.8 million for semaglutide.

Dosing Protocol

Tirzepatide follows a gradual titration schedule to minimize gastrointestinal side effects. Understanding the dose-response relationship helps identify the optimal maintenance dose for individual goals.

Understanding the Dose Range

Clinical trial results were dose-dependent: 5 mg produced 15% weight loss, 10 mg produced 19.5%, and 15 mg produced 22.5%. The jump from 5 mg to 10 mg added 4.5 percentage points of weight loss, while the jump from 10 mg to 15 mg added only 3 more points, demonstrating diminishing returns at higher doses. Not everyone needs the maximum dose. If you need 15% weight loss, 5 mg may suffice. If you need 20% or more, pushing to 10 mg or 15 mg may be warranted.

Standard Titration Protocol

Subcutaneous injection, once weekly:

Weeks Dose Weeks 1 to 4 2.5 mg Weeks 5 to 8 5 mg Weeks 9 to 12 7.5 mg Weeks 13 to 16 10 mg Weeks 17 to 20 12.5 mg Week 21 onward 15 mg (maximum)

The 2.5 mg starting dose is intentionally low to allow the body to adapt. Do not skip it. If side effects are significant at any step, remain at that dose for an additional four weeks before increasing. The trial data showed that slower titration improved tolerability without sacrificing long-term results. Many people achieve excellent results at 10 mg without ever needing 15 mg. Inject on the same day each week for stable blood levels.

Draw Volumes by Vial Size

10 mg Vial (2 mL reconstitution = 5 mg/mL)

Dose Volume Units on Syringe 2.5 mg 0.50 mL 50 units 5 mg 1.00 mL 100 units 7.5 mg 1.50 mL Requires two draws

Vial duration at 5 mg/week: 2 weeks. This concentration works well for the early titration phase. 20 mg Vial (2 mL reconstitution = 10 mg/mL)

Dose Volume Units on Syringe 2.5 mg 0.25 mL 25 units 5 mg 0.50 mL 50 units 7.5 mg 0.75 mL 75 units 10 mg 1.00 mL 100 units 12.5 mg 1.25 mL Requires two draws 15 mg 1.50 mL Requires two draws

Vial duration at 10 mg/week: 2 weeks. For doses above 10 mg, draw 100 units (10 mg), inject, then draw the remaining amount and inject again. 30 mg Vial (2 mL reconstitution = 15 mg/mL)

Dose Volume Units on Syringe 2.5 mg 0.167 mL ~17 units 5 mg 0.33 mL 33 units 7.5 mg 0.50 mL 50 units 10 mg 0.67 mL 67 units 12.5 mg 0.83 mL 83 units 15 mg 1.00 mL 100 units

Vial duration at 15 mg/week: 2 weeks. This is the most practical concentration once you reach maintenance dosing at higher levels.

Reconstitution Instructions

1. Draw the appropriate amount of bacteriostatic water into a sterile syringe (2 mL recommended). 2. Inject slowly down the inside wall of the vial to avoid foaming. 3. Gently swirl or roll the vial until fully dissolved. Do not shake. 4. The solution should be clear and colorless to slightly yellow. Do not use if cloudy or it contains particles. 5. Label with the reconstitution date and concentration. 6. Refrigerate at 36 to 46 degrees Fahrenheit (2 to 8 degrees Celsius). 7. Use within 28 days.

Injection Technique

8. Wash hands thoroughly with soap and water. 9. Clean the vial stopper with an alcohol swab and allow it to air dry. 10. Draw the appropriate dose into a sterile insulin syringe. 11. Clean the injection site with an alcohol swab. 12. Pinch a skinfold and insert the needle at 45 to 90 degrees into subcutaneous tissue. 13. Do not aspirate for subcutaneous injections. 14. Inject slowly and steadily. 15. Withdraw the needle and apply light pressure with gauze if needed. 16. Dispose of the syringe immediately in a sharps container. Never recap needles. 17. Rotate injection sites weekly (abdomen, thighs, upper arms), at least 1 inch apart.

Side Effects and Safety Profile

The side effects of tirzepatide are similar to other GLP-1 drugs. The dual mechanism does not appear to increase side effect severity compared to semaglutide, and the SURMOUNT-5 data showed that gastrointestinal adverse events causing treatment discontinuation were actually lower with tirzepatide (2.7%) than semaglutide (5.6%).

Common Effects

These are dose-dependent and typically improve after the first few weeks at each dose level. Most people find them manageable with proper titration. Starting at 2.5 mg and escalating slowly significantly reduces the severity and duration of gastrointestinal symptoms.

Less Common

When to Contact a Medical Professional

Clinical Trial Safety Data

In SURMOUNT-5, the most common adverse events in both treatment groups were gastrointestinal. Serious adverse events occurred in 4.8% of the tirzepatide group compared to 3.5% of the semaglutide group, with six patients discontinuing due to adverse events in each group. Most adverse events were mild to moderately severe and occurred during dose escalation.

Contraindications and Precautions

Do Not Use If You Have

Use with Caution If You Have

Drug Interactions

If you take insulin or sulfonylureas, those doses may need significant reduction to prevent low blood sugar. Tirzepatide slows gastric emptying, which can affect how quickly oral medications are absorbed. Women using oral contraceptives should use backup methods or switch to non-oral contraception during treatment, as delayed gastric emptying may reduce the effectiveness of oral hormonal contraceptives.

Comparison to Other Weight Loss Compounds

Drug Receptors Max Dose Avg Weight Dosing Status

Loss

Tirzepatide GLP-1 + GIP 15 mg ~20–22% Once weekly FDA weekly approved Retatrutide GLP-1 + GIP 12 mg ~24% Once weekly Phase 3 + Glucagon weekly CagriSema GLP-1 + 2.4/2.4 mg ~20% Once weekly Phase 3

Amylin

Semaglutide GLP-1 2.4 mg ~14–15% Once weekly FDA weekly approved Cagrilintide Amylin 2.4 mg ~11% Once weekly Phase 3 weekly Liraglutide GLP-1 3.0 mg daily ~8% Once daily FDA approved

Tirzepatide is currently the most effective FDA-approved obesity medication. Only the investigational compound retatrutide (a triple agonist targeting GLP-1, GIP, and glucagon receptors) has shown higher weight loss in trials. Tirzepatide’s dual mechanism also appears to produce better tolerability than GLP-1 monotherapy, as demonstrated by lower rates of gastrointestinal-related discontinuations in the head-to-head SURMOUNT-5 trial.

Success Tips

Titrate Slowly

The most common mistake is moving up too fast. Your body needs time to adapt to the new signals. If a dose is rough, stay there longer before increasing. The trial data showed that slower titration improved tolerability without sacrificing long-term results.

Manage the Nausea

Eat smaller meals. Stop eating at the first sign of fullness. This is critical: the drug makes you feel full faster, and if you push past that signal, you will feel sick. Avoid greasy, fried, or spicy foods during titration. Stay upright after eating. Ginger tea can help alleviate mild nausea.

Protect Your Muscle

With 20% or more weight loss possible, prioritizing protein is essential. Aim for 1.0 to 1.2 grams per kilogram of body weight daily. Reduced appetite makes it easy to undereat, and if protein intake is inadequate, you will lose muscle along with fat. Make protein your focus at every meal.

Stay Hydrated

These drugs can reduce your thirst signals. Set reminders to drink water throughout the day. Dehydration makes nausea worse, causes constipation, and stresses the kidneys.

Keep Training

Walk daily. Lift weights two to three times per week. The weight loss will happen either way, but resistance training ensures more of what you lose is fat and less is muscle. Do not rely on the drug alone.

Track Your Progress

Weigh yourself weekly at the same time. Take measurements monthly. Progress photos help provide perspective. Weight was still declining at week 72 in the trials, so patience pays off. The SURMOUNT-4 data showed that stopping treatment leads to significant weight regain in most people, so plan for long-term use.

Find Your Minimum Effective Dose

At each dose level, assess whether you are losing weight at a satisfactory rate, whether side effects are manageable, and whether your appetite is appropriately suppressed. If you are losing one to two pounds per week at 7.5 mg or 10 mg with tolerable side effects, you may not need to increase further. The goal is finding the minimum effective dose that achieves your results, not automatically pushing to the maximum.

Storage and Handling

Before Reconstitution

Fahrenheit)

Fahrenheit)

After Reconstitution

Legal Status

United States: FDA approved. Mounjaro is approved for type 2 diabetes (May 2022). Zepbound is approved for obesity (November 2023). Available by prescription from licensed healthcare providers. Research Peptide Market: Research-grade tirzepatide is available from peptide suppliers in lyophilized powder form for research purposes.

Frequently Asked Questions

How is tirzepatide different from semaglutide? Semaglutide activates only GLP-1 receptors. Tirzepatide activates both GLP-1 and GIP receptors. This dual action produces greater weight loss (20.2% versus 13.7% head to head), may improve tolerability, and provides broader metabolic benefits. Is 20% weight loss realistic? That was the average at the maximum tolerated dose in the SURMOUNT-5 trial. Some people lose more, some lose less. Individual response varies, but the clinical trial data from thousands of participants is robust. What if I miss a dose? Take it as soon as you remember if it has been less than four days. If more than four days have passed, skip it and take your next dose on schedule. Will the weight come back if I stop? The SURMOUNT-4 post-hoc analysis showed that most participants who stopped tirzepatide regained 25% or more of their lost weight within one year, with reversal of cardiometabolic improvements. Long-term or indefinite use may be necessary to maintain results. Building good habits during treatment helps reduce the magnitude of regain. Is nausea unavoidable? Most people experience some nausea, especially during titration. Starting at 2.5 mg and escalating slowly helps significantly. It typically improves after the first few weeks at each dose level. Eating smaller, less greasy meals and staying hydrated reduces severity. Can I stack it with other peptides? Tirzepatide already activates two receptor pathways. Adding semaglutide or another GLP-1 drug would be redundant and increase side effects. If you want to combine, consider compounds that work through completely different mechanisms, such as resistance training with adequate protein intake. Does it affect testosterone? In men with obesity, tirzepatide increased testosterone levels. This is likely due to fat loss reducing aromatase-mediated estrogen conversion. Data presented at ENDO 2025 showed improvements in sexual function alongside weight loss. What about muscle loss? All significant weight loss involves some muscle loss. The dual GLP-1 and GIP mechanism may help preserve lean mass compared to GLP-1-only drugs. Prioritizing protein intake (1.0 to 1.2 g/kg daily) and resistance training two to three times per week is essential for minimizing muscle loss.

References

1. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022;387(3):205–216. 2. Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as compared with semaglutide for the treatment of obesity. New England Journal of Medicine. 2025;393(1):26–36. 3. Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine. 2021;385(6):503–515. 4. Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity. New England Journal of Medicine. 2024;391(14):1288–1298. 5. Rosenstock J, Wysham C, Frías JP, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomized, phase 3 trial. The Lancet. 2021;398(10295):143–155. 6. Horn DB, Linetzky B, Davies MJ, et al. Cardiometabolic parameter change by weight regain on tirzepatide withdrawal in adults with obesity: a post hoc analysis of the SURMOUNT-4 trial. JAMA Internal Medicine. 2025. 7. Mamas M, et al. Post-hoc analysis of SURMOUNT-5: Cardiovascular risk reduction with tirzepatide versus semaglutide. Presented at the European Society of Cardiology Congress 2025. 8. Hunter Gibble T, Cao D, Forrester T, et al. Tirzepatide and health-related quality of life in adults with obesity or overweight: results from the SURMOUNT-3 phase 3 randomized trial. Diabetes, Obesity and Metabolism. 2025;27(8):4268–4279. 9. ENDO 2025. Tirzepatide effects on testosterone in men with obesity. Endocrine Society Annual Meeting. 2025. 10. Eli Lilly and Company. Zepbound (tirzepatide) prescribing information. US Food and Drug Administration. 2023.

Property Support

Our Property Support services are designed to help homeowners, property managers, and businesses maintain safe, clean, and well-functioning properties year-round.

Get In Touch